VNZ/TEZ/D-IVA

Phase 3Recruiting

0 views this week 0 watching⚡ Active💊Featured in Rare Disease Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis

Trial Timeline

Aug 11, 2023 → Jul 30, 2029

NCT ID

NCT05844449

About VNZ/TEZ/D-IVA

VNZ/TEZ/D-IVA is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05844449. Target conditions include Cystic Fibrosis.

What happened to similar drugs?

20 of 20 similar drugs in Cystic Fibrosis were approved

Approved (20) Terminated (7) Active (0)

✅CefiderocolShionogiApproved

✅CREONAbbVieApproved

✅Pancrelipase + PancrelipaseAbbVieApproved

✅Tedizolid PO + Tedizolid IVMerckApproved

✅Alendronate + PlaceboMerckApproved

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Ceftolozane/TazobactamMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06299696	Phase 1	Completed	Mar 26, 2024	Apr 16, 2024	Cystic Fibrosis
NCT05844449	Phase 3	Recruiting	Aug 11, 2023	Jul 30, 2029	Cystic Fibrosis

Competing Products

20 competing products in Cystic Fibrosis

See all competitors

Product	Company	Stage	Hype Score
VX-522 mRNA therapy + IVA	Moderna	Phase 1/2	36
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
Enfortumab Vedotin	Astellas Pharma	Phase 2	42
Cefiderocol	Shionogi	Approved	43
Lenvatinib	Eisai	Phase 2	39
Lenvatinib + Pembrolizumab	Eisai	Phase 2	39
CREON	AbbVie	Approved	43
Pancrelipase + Pancrelipase	AbbVie	Approved	43
Creon IR + Creon® (DR/GR)	AbbVie	Phase 2	35
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222	AbbVie	Phase 2	35
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119	AbbVie	Phase 2	27
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	32
AZD5634 for inhalation + AZD5634 for infusion	AstraZeneca	Phase 1	29
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
AZD1236 + Placebo	AstraZeneca	Phase 2	27
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD9668 + AZD9668 Placebo equivalent	AstraZeneca	Phase 2	35